BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

pills manyNovember 16 2015

 

The Scottish Medicines Consortium has announced the latest drugs it has approved for use in NHS Scotland.

 

Its November Briefing Note has the following recommendations for use:

  • edoxaban (Lixiana) - for treating deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults;
  • edoxaban (Lixiana) - for the prevention of stroke or systemic embolism in adults with non-valvular atrial fibrillation (NVAF) who have other complicating factors, such as congestive heart failure, diabetes hypertension, prior stroke or transient ischaemic attack, or are aged of 75 years;
  • bevacizumab (Avastin) - for use in combination with carboplatin and paclitaxel for certain cancers of the ovaries or fallopian tubes or in primary peritoneal cancer;
  • pembrolizumab (Keytruda) for advanced melanoma patients previously untreated with ipilimumab (Yervoy)

It has also recommended against using pembrolizumab (Keytruda) for advanced melanoma where patients have already been treated with ipilimumab.

NHS England has issued interim policy to allow commissioning of adalimumab for use in children with severe refractory uveitis. The policy, which “will benefit children for whom uveitis threatens their sight, and for whom other treatments have proven ineffective,” will be reviewed in 2016.

“A policy on this indication was held over from the 2015/16 specialised commissioning prioritisation round pending further evidence from the ‘Sycamore’ clinical trial. This evidence has now been shared with NHS England in confidence and in advance of its publication,” said NHS England. The review will take place once the Sycamore trial data has been published.

Links:

SMC announcement

SMC November Briefing Note

NHS England announcement

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...